12,372 trials
Acute Schizophrenia
Primary: Mean Change From Baseline to Week 6 Positive and Negative Syndrome Scale (PANSS) Total Score. — -19.65; -20.73; -14.90; -12.01 Units on a scale — p=<0.0001
Bacterial Vaginosis
Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…
Malaria
Primary: Incidence of Placental Malaria Infection Based on Histology — 11.58; 15.42; 15.42 percentage of pregnancies — p=0.2441
Symptomatic Vitreomacular Adhesion
Primary: Proportion of Subjects With Non-Surgical Resolution of Vitreomacular Adhesion (VMA) — 52.2; 1.8 percentage of subjects
Type 2 Diabetes Mellitus
Primary: Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue During Phase A — 59.5; 53.8; 54.5; 60.0 Percentage of…
Poor Glycemic Control
Primary: Efficacy, Measured by a Change in HbA1c Levels — 5.09; 5.2; 5.5; 5.8 percent of glycosylated hemoglobin
Prostate Cancer
Primary: Percentage of Subjects Demonstrating Castration at Day 29 and Maintaining Castration at Day 183 — 97.6; 96.6 Percentage of subjects
Hepatitis C, Chronic
Primary: Sustained Virological Response 12 Weeks Post Treatment (SVR12) — 10.3; 65.4; 61.4; 33.8 percentage of participants — p=<0.0001
Hidradenitis Suppurativa (HS)
Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 27.6; 58.9; 36.8; 17.1 percentage of participants — p=<0.001
Papulopustular Rosacea
Primary: Percent Change in Inflammatory Lesions From Baseline to Week 16 — -83; -73.7 percentage of change
Hidradenitis Suppurativa (HS)
Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 26.0; 41.8; 29.8; 21.4 percentage of participants — p==0.003
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis — -16.3; -14.4; -50.6; -15.9 percent change — p=<0.0001
Heterozygous Familial Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis — -48.7; 2.8 percent change — p=<0.0001
Hepatitis C
Primary: Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Treatment-naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) — 96.4 Percentage…
Multiple Myeloma
Primary: Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination…